SCHEMBL30774414

SCHEMBL30774414

N#Cc1ccc2[nH]c(-c3cncc4c3OCCN4C(=O)C3CN(Cc4cccc(F)c4)C3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 7/20 0.43
▸ CDK7 P50613 2/20 0.39
▸ VCP P55072 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ GPR6 P46095 1/20 0.34
▸ MAOB P27338 1/20 0.33
▸ CYP19A1 P11511 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ S1PR3 Q99500 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ PTGER2 P43116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774609 0.94 CHEK1 (0.40) CHEK1CDK7KDM4EALDH1A1HPGD
SCHEMBL30774008 0.88 CHEK1 (0.44) CHEK1CDK7VCPKDM4EALDH1A1
SCHEMBL30774010 0.88 ALDH1A1 (0.38) KDM4EALDH1A1HPGDMAOBS1PR1
SCHEMBL30774590 0.86 USP30 (0.42) KDM4EALDH1A1HPGDUSP30GPR6
SCHEMBL30774495 0.85 S1PR1 (0.43) KDM4EALDH1A1HPGDUSP30GPR6
SCHEMBL30774029 0.85 PKM (0.37) CHEK1KDM4EALDH1A1HPGDMAOB
SCHEMBL30774644 0.81 USP30 (0.46) KDM4EALDH1A1HPGDUSP30
SCHEMBL30774398 0.81 USP30 (0.46) KDM4EALDH1A1HPGDUSP30
SCHEMBL30774840 0.81 ROCK2 (0.44) USP30DRD2DRD4DRD3PTGER2
SCHEMBL30774472 0.77 ALDH1A1 (0.43) KDM4EALDH1A1HPGDMAOBS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 CHEK1 2841/4885CDK7 355/4885VCP 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback